In brief: An expanded indication for Enhertu.Med Lett Drugs Ther 2026 May 25; 68(1755):87.ML
Pub Type(s)
Journal Article
Language
eng
PubMed ID
42139029
Citation
"In Brief: an Expanded Indication for Enhertu." The Medical Letter On Drugs and Therapeutics, vol. 68, no. 1755, 2026, p. 87.
In brief: An expanded indication for Enhertu. Med Lett Drugs Ther. 2026;68(1755):87.
(2026). In brief: An expanded indication for Enhertu. The Medical Letter On Drugs and Therapeutics, 68(1755), 87. https://doi.org/10.58347/tml.2026.1755d
In Brief: an Expanded Indication for Enhertu. Med Lett Drugs Ther. 2026 May 25;68(1755):87. PubMed PMID: 42139029.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - In brief: An expanded indication for Enhertu.
PY - 2026/5/15/medline
PY - 2026/5/15/pubmed
PY - 2026/5/15/entrez
KW - Enhertu
KW - Herceptin
KW - Perjeta
KW - breast cancer
KW - dosage
KW - efficacy
KW - fam-trastuzumab deruxtecan
KW - pertuzumab
KW - safety
KW - trastuzumab
SP - 87
EP - 87
JF - The Medical letter on drugs and therapeutics
JO - Med Lett Drugs Ther
VL - 68
IS - 1755
SN - 1523-2859
UR - https://www.unboundmedicine.com/prime/citation/42139029/In_brief:_An_expanded_indication_for_Enhertu.
DB - PRIME
DP - Unbound Medicine
ER -
